Table 2.
Analysis of mortality. Uni- and multivariate analysis including all patients.
| Univariate Analysis | Multivariate Analysis | ||||
|---|---|---|---|---|---|
| Global Mortality | p | OR | IC95% | p | |
| 86/240 (35.8%) | |||||
| Age >65 y-o | 39.90% | 0.29 | 2.69 | 1.29–5.57 | 0.008 |
| Gender (male) | 44.40% | 0.002 | - | - | - |
| Proven, probable or possible IPA | 37.10% | 0.68 | - | - | - |
| Proven, or probable IPA | 43.50% | 0.23 | - | - | - |
| Type of pulmonary infiltrate | - | - | - | ||
| -No infiltrate | 18.80% | 0.001 | - | - | - |
| -Nodular or bilateral, ground-glass opacities | 48.10% | <0.001 | - | - | - |
| -Pleural fluid | 54.90% | 0.001 | - | - | - |
| Renal insufficiency (acute or chronic) | 56.20% | <0.001 | 2.58 | 1.30–5.08 | 0.006 |
| Neutrophils <100/µL | 50.00% | 0.001 | - | - | - |
| Lymphocytes <1000/µL | 48.50% | 0.035 | - | - | - |
| Platelets count <100.000/µL | 73.90% | <0.001 | 6.41 | 2.07–19.8 | 0.001 |
| CRP (±SD) | 117 (±106) | 0.018 | - | - | - |
| Oxygen high requirements | 53.20% | <0.001 | - | - | - |
| ICU admission | 51.90% | <0.001 | - | - | - |
| Mechanical ventilation | 53.70% | <0.001 | - | - | - |
| Inotropic therapy | 61.50% | <0.001 | 5.32 | 2.52–11.19 | <0.001 |
| Pronation required | 58.40% | <0.001 | - | - | - |
| Corticoid therapy previous (any dose) | 44.90% | <0.001 | - | - | - |
| Previous corticoids | 16.2 (±9.7) | 0.004 | - | - | - |
| Bacterial infection | 42.20% | <0.001 | - | - | - |
| CMV infection | 62.90% | <0.079 | - | - | - |
| Hospitalization total days | 31 (±23) | 0.09 | - | - | - |
| ICU total days | 20 (±18) | 0.001 | - | - | - |
| SARS-CoV-2 infection | 51.50% | <0.001 | 3.14 | 1.40–7.04 | 0.005 |
ECMO: extracorporeal membrane oxygenation. IL-6: Interleukin-6. CMV: Cytomegalovirus. CRP: C-reactive protein. ICU: Intensive care unit.